Fathi Elloumi

The paper uses single-cell RNA sequencing to show heterogeneous SLFN11 expression in cancer cells, linking it to stress response and genome maintenance.

SCLC TumorMiner is a genomics platform that provides molecular classification, biomarker identification, and drug-response analysis for small cell lung cancer using integrated datasets from multiple institutions.

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

This paper identifies SEMA7A as a prognostic biomarker in adrenocortical carcinoma using transcriptome data from TCGA and NCI samples, showing its association with poor prognosis and specific signaling pathways.

The paper examines SLFN11 expression in B-cell development and lymphomas, finding it is epigenetically suppressed in germinal center B cells and that epigenetic modifiers enhance its expression, increasing sensitivity to cytosine arabinoside.

CellMinerCDB integrates pharmacogenomic data from multiple cancer cell line databases to identify drug response determinants, reproducibility, and novel genomic signatures.